A Phase 4 interventional study of Fingolimod 0.5mg in Relapsing Multiple Sclerosis (RMS), sponsored by Novartis Pharmaceuticals. Completed at 13 sites in China. Open to participants aged 10 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-01-13.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies testing fingolimod in Multiple Sclerosis — 2 open to participants now, 4 under way, 3 of them phase 3. fingolimod · Multiple Sclerosis.
Among the 34 studies testing fingolimod in Multiple Sclerosis, this one is the 24th largest by enrollment, is the only one that started in 2021, is one of 17 in phase 4, and was the 32nd registered.
3,271 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.
Browse Multiple Sclerosis studies →2 of the 34 studies testing fingolimod in Multiple Sclerosis are open now, in 3 countries. Recruiting first, the newest first:
TG Therapeutics, Inc. · Sites in United States, Poland, Slovakia
Ages 10–17
Biogen
Ages 10–17
By country, each count listing its studies:
fingolimod: first FDA approval 2010 (GILENYA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 433 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.
This study: 10 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 5 · Phase 3 13 · Phase 4 17
First in 2003; this study’s year is marked. 1 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 98 is above the median of 50 across 2,207 interventional studies indexed under Multiple Sclerosis.
Median enrollment 167 across the 34 interventional studies. Of the 28 that completed or were terminated, 23 (82%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 34 have an industry lead sponsor. The 6 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,720 studies on the registry; 221 are open to participants now.
Of its 586 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
106 studies in Multiple Sclerosis by Novartis: 9 open now, 24 under way, 6 of them phase 3. Of 78 finished, 45 (58%) have results posted.
Among the 106 studies in Multiple Sclerosis by Novartis, this one is the 41st largest by enrollment of the 64 interventional ones that give a count, is one of 12 that started in 2021, is one of 26 in phase 4, and was the 56th registered.
Novartis’s Multiple Sclerosis studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 34 studies testing fingolimod in Multiple Sclerosis, from their registry updates:
Among Novartis’s 106 in Multiple Sclerosis:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study was to assess the efficacy and safety of 0.5mg Fingolimod (Gilenya) in Chinese patients with relapsing multiple sclerosis (RMS)
This was a 24-month, open-label, multicenter, interventional, single-arm study to collect efficacy and, safety of oral fingolimod 0.5 mg/day in approximately 100 relapsing multiple sclerosis (RMS) participants in China.
The study consisted of three Phases:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Fingolimod 0.5 mg capsule taken orally once daily
Drug: Fingolimod 0.5mg
Subjects received fingolimod 0.5mg capsule QD up to month 24
Also known as: FTY720
Adjusted Annualized Relapse Rate (ARR) in Adult Group
A confirmed relapse is any relapse that is accompanied by an increase of at least 0.5 on the EDSS or an increase of 1 point on two different Functional Systems (FS) of the EDSS or 2 points on one of the FS (excluding Bowel/Bladder or Cerebral FS) as confirmed by the treating physician. The adjusted annualized relapse rate (ARR) was estimated by a negative binomial regression model with log-link function, the cumulative number of confirmed MS relapses per subject as the response variable, number of relapses in the previous two years before enrollment and baseline EDSS as continuous covariates. Natural log of time on study in years was used as the offset variable to account for the varying lengths of subjects' time in the study. The adjusted ARR (i.e.model-based estimate adjusted for covariates) and the corresponding 95% confidence interval were obtained. As per SAP this analysis was only performed for the Adult group. Descriptive data is presented in subsequent OMs.
Time frame: Baseline to Month 24
Number of Participants With Treatment Emergent Adverse Events (AE) and Serious Adverse Events (SAE)
An adverse event (AE) is any untoward medical occurrence in a clinical investigation subject after providing written informed consent for participation in the study. For reporting purposes, the main focus was on treatment emergent adverse event (TEAE), defined as any AE which started on or after the day of first dose of study medication or events present prior to the start of treatment but increased in severity.
Time frame: From first dose of study treatment to 45 days after last study dose up to aproximately 25.5 months
Annualized Rate of the Number of New or Newly Enlarged T2 Lesions
Obtained from fitting a negative binomial regression model with log-link function, the total number of new or newly enlarged T2 lesions during the treatment period (per participant) as the response variable. The model included baseline age and volume of T2 lesions at baseline as continuous covariates. Natural log of time from screening scan in years was used as the offset. Baseline is defined as the last non-missing assessment obtained prior to the first administration of study drug. As per SAP this analysis was only performed for the Adult group.
Time frame: Baseline to end of treatment (up to Month 24)
Change From Baseline in Number of New or Newly Enlarged T2 Lesions
Number of new/newly enlarged T2 lesions since baseline as measured by MRI
Time frame: Baseline up to Month 24
Change From Baseline in T2 Lesion Volume
T2 lesion volume as measured by MRI and calculated as post-baseline value - baseline value
Time frame: Baseline up to Month 24
Number of Gd-enhancing T1 Lesions Per Scan in Adult Group
Obtained from fitting a negative binomial regression model with log-link function, the total number of Gd-enhancing T1 lesions during the treatment period (per patient) as the response variable. The model included baseline age and number of Gd-enhancing T1 lesions at baseline as continuous covariates. Natural log of the number of MRI scans was used as the offset. MRI scans were performed at baseline, month 12 and month 24 and End of treatment for participants that discontinued treatment. Unscheduled MRIs could be performed at the investigator's judgement. As per SAP this analysis was only performed for the Adult group.
Time frame: Baseline up to Month 24
Number of Gd-enhancing T1 Lesions
Number of Gd-enhancing T1 lesions as measured by MRI
Time frame: Baseline up to Month 24
Change From Baseline in Gd-enhancing T1 Lesion Volume
Gd-enhancing T1 lesion volume as measured by MRI and calculated as post-baseline value - baseline value
Time frame: Baseline up to Month 24
Number of T1 Hypo-intense Lesions
Number of T1 hypo-intense lesions as measured by MRI
Time frame: Baseline up to Month 24
Change From Baseline in T1 Hypo-intense Lesion Volume
T1 hypo-intense lesions as measured by MRI and calculated as post-baseline value - baseline value
Time frame: Baseline up to Month 24
Participants were enrolled at 13 sites in China
| Milestone | Fingolimod (< 18 Years) | Fingolimod > 18 Years |
|---|---|---|
| Started | 11 | 87 |
| Completed | 10 | 75 |
| Not completed | 1 | 12 |
| Withdrew: Adverse event | 0 | 2 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Physician decision | 0 | 2 |
| Withdrew: Subject decision | 1 | 7 |
A relapse is an appearance of a new neurological abnormality or worsening of previously stable or improving pre-existing neurological abnormality, separated by at least 30 days from onset of a preceding clinical demyelinating event which is present for at least 24 hours in the absence of fever or infection. A relapse is confirmed by the treating physician when it is accompanied by an increase of at least 0.5 on the Expanded Disability Status Scale (EDSS) or an increase of 1 point on two different Functional Systems (FS) of the EDSS or 2 points on one of the FS (excluding Bowel/Bladder or Cerebral FS). Participant-based ARR was calculated by taking the total number of relapses observed for a participant divided by the total number of days in study of that participant and multiplied by 365.25.
| relapses per participant-year | Fingolimod (< 18 Years) | Fingolimod > 18 Years |
|---|---|---|
| All relapses - Participant based | 0.1952 ± 0.50314 | 0.0969 ± 0.50002 |
| Confirmed relapses - Participant based | 0.0460 ± 0.15253 | 0.0372 ± 0.24424 |
A relapse is an appearance of a new neurological abnormality or worsening of previously stable or improving pre-existing neurological abnormality, separated by at least 30 days from onset of a preceding clinical demyelinating event which is present for at least 24 hours in the absence of fever or infection. A relapse is confirmed by the treating physician when it is accompanied by an increase of at least 0.5 on the Expanded Disability Status Scale (EDSS) or an increase of 1 point on two different Functional Systems (FS) of the EDSS or 2 points on one of the FS (excluding Bowel/Bladder or Cerebral FS). Time-based ARR was calculated by taking the total number of relapses observed for all subjects within an age group divided by the total number of days in study of all subjects within the group and multiplied by 365.25 days.
| relapses per participant-year | Fingolimod (< 18 Years) | Fingolimod > 18 Years |
|---|---|---|
| All relapses - Time based | 0.161 | 0.065 |
| Confirmed relapses - Time based | 0.054 | 0.019 |
A confirmed relapse is any relapse that is accompanied by an increase of at least 0.5 on the EDSS or an increase of 1 point on two different Functional Systems (FS) of the EDSS or 2 points on one of the FS (excluding Bowel/Bladder or Cerebral FS) as confirmed by the treating physician. The adjusted annualized relapse rate (ARR) was estimated by a negative binomial regression model with log-link function, the cumulative number of confirmed MS relapses per subject as the response variable, number of relapses in the previous two years before enrollment and baseline EDSS as continuous covariates. Natural log of time on study in years was used as the offset variable to account for the varying lengths of subjects' time in the study. The adjusted ARR (i.e.model-based estimate adjusted for covariates) and the corresponding 95% confidence interval were obtained. As per SAP this analysis was only performed for the Adult group. Descriptive data is presented in subsequent OMs.
| relapses per participant-year | Fingolimod > 18 Years |
|---|---|
| Adjusted Annualized Relapse Rate (ARR) in Adult Group | 0.018 (0.006 to 0.061) |
An adverse event (AE) is any untoward medical occurrence in a clinical investigation subject after providing written informed consent for participation in the study. For reporting purposes, the main focus was on treatment emergent adverse event (TEAE), defined as any AE which started on or after the day of first dose of study medication or events present prior to the start of treatment but increased in severity.
| Participants | Fingolimod (< 18 Years) | Fingolimod > 18 Years |
|---|---|---|
| Adverse events (AEs) | 11 | 86 |
| Study treatment related AEs | 10 | 81 |
| Serious adverse events (SAEs) | 3 | 12 |
| AEs leading to interruption of study treatment | 3 | 11 |
| AEs leading to study discontinuation | 1 | 5 |
| AEs leading to death | 0 | 0 |
Obtained from fitting a negative binomial regression model with log-link function, the total number of new or newly enlarged T2 lesions during the treatment period (per participant) as the response variable. The model included baseline age and volume of T2 lesions at baseline as continuous covariates. Natural log of time from screening scan in years was used as the offset. Baseline is defined as the last non-missing assessment obtained prior to the first administration of study drug. As per SAP this analysis was only performed for the Adult group.
| Lesions per participant-year | Fingolimod > 18 Years |
|---|---|
| Annualized Rate of the Number of New or Newly Enlarged T2 Lesions | 1.316 (0.762 to 2.272) |
Number of new/newly enlarged T2 lesions since baseline as measured by MRI
| new / newly enlarged T2 lesions | Fingolimod (< 18 Years) | Fingolimod > 18 Years |
|---|---|---|
| 12 months | 1.8 ± 1.93 | 1.8 ± 4.18 |
| 24 months | 2.1 ± 2.18 | 2.4 ± 4.84 |
T2 lesion volume as measured by MRI and calculated as post-baseline value - baseline value
| milliliters | Fingolimod (< 18 Years) | Fingolimod > 18 Years |
|---|---|---|
| 12 months | 0.6140 (-17.607 to 34.748) | 0.3930 (-6.343 to 25.158) |
| 24 months | -1.6736 (-17.100 to 36.719) | 0.4065 (-5.741 to 26.322) |
Obtained from fitting a negative binomial regression model with log-link function, the total number of Gd-enhancing T1 lesions during the treatment period (per patient) as the response variable. The model included baseline age and number of Gd-enhancing T1 lesions at baseline as continuous covariates. Natural log of the number of MRI scans was used as the offset. MRI scans were performed at baseline, month 12 and month 24 and End of treatment for participants that discontinued treatment. Unscheduled MRIs could be performed at the investigator's judgement. As per SAP this analysis was only performed for the Adult group.
| Lesions per participant per scan | Fingolimod > 18 Years |
|---|---|
| Number of Gd-enhancing T1 Lesions Per Scan in Adult Group | 0.376 (0.216 to 0.655) |
Number of Gd-enhancing T1 lesions as measured by MRI
| T1 lesions | Fingolimod (< 18 Years) | Fingolimod > 18 Years |
|---|---|---|
| 12 months | 0.4 ± 0.70 | 0.4 ± 0.84 |
| 24 months | 0 ± 0.00 | 0.4 ± 1.83 |
Gd-enhancing T1 lesion volume as measured by MRI and calculated as post-baseline value - baseline value
| microliters | Fingolimod (< 18 Years) | Fingolimod > 18 Years |
|---|---|---|
| 12 months | -56.0 (-1392.5 to 418.0) | 0.00 (-1869.0 to 546.0) |
| 24 months | -56.0 (-632.7 to 0.0) | 0.00 (-1869.0 to 1082.0) |
Number of T1 hypo-intense lesions as measured by MRI
| T1 hypo-intense lesions | Fingolimod (< 18 Years) | Fingolimod > 18 Years |
|---|---|---|
| 12 months | 14.6 ± 12.97 | 17.0 ± 13.62 |
| 24 months | 13.4 ± 10.86 | 16.7 ± 13.27 |
T1 hypo-intense lesions as measured by MRI and calculated as post-baseline value - baseline value
| microliters | Fingolimod (< 18 Years) | Fingolimod > 18 Years |
|---|---|---|
| 12 months | -77.500 (-6849.30 to 20341.80) | 44.000 (-4921.30 to 19035.00) |
| 24 months | -641.415 (-7444.50 to 1161.50) | 187.100 (-5772.20 to 19264.00) |
Collected over Adverse events were reported from first dose of study treatment to 60 days after last study dose up to approximately 26 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Less Than 18 Years | 0/11 (0%) | 3/11 (27.3%) | 11/11 (100%) |
| Greater Than or Equal to 18 Years | 0/87 (0%) | 12/87 (13.8%) | 85/87 (97.7%) |
| Overall | 0/98 (0%) | 15/98 (15.3%) | 96/98 (98%) |
| Event | Less Than 18 Years | Greater Than or Equal to 18 Years | Overall |
|---|---|---|---|
| SeizureNervous system disorders | 2/11 | 0/87 | 2/98 |
| Febrile infectionInfections and infestations | 1/11 | 0/87 | 1/98 |
| InfectionInfections and infestations | 1/11 | 0/87 | 1/98 |
| PneumoniaInfections and infestations | 1/11 | 0/87 | 1/98 |
| TonsillitisInfections and infestations | 1/11 | 0/87 | 1/98 |
| Muscle twitchingMusculoskeletal and connective tissue disorders | 1/11 | 0/87 | 1/98 |
| EpilepsyNervous system disorders | 1/11 | 0/87 | 1/98 |
| SyncopeNervous system disorders | 1/11 | 0/87 | 1/98 |
| Liver injuryHepatobiliary disorders | 0/11 | 3/87 | 3/98 |
| Drug-induced liver injuryHepatobiliary disorders | 0/11 | 2/87 | 2/98 |
| Event | Less Than 18 Years | Greater Than or Equal to 18 Years | Overall |
|---|---|---|---|
| LymphopeniaBlood and lymphatic system disorders | 7/11 | 24/87 | 31/98 |
| Lymphocyte count decreasedInvestigations | 2/11 | 53/87 | 55/98 |
| LeukopeniaBlood and lymphatic system disorders | 5/11 | 22/87 | 27/98 |
| Weight decreasedInvestigations | 5/11 | 8/87 | 13/98 |
| COVID-19Infections and infestations | 2/11 | 35/87 | 37/98 |
| Alanine aminotransferase increasedInvestigations | 2/11 | 33/87 | 35/98 |
| PyrexiaGeneral disorders and administration site conditions | 4/11 | 12/87 | 16/98 |
| NasopharyngitisInfections and infestations | 4/11 | 9/87 | 13/98 |
| PharyngitisInfections and infestations | 4/11 | 0/87 | 4/98 |
| Upper respiratory tract infectionInfections and infestations | 4/11 | 21/87 | 25/98 |
| Age, Continuous(years) | Fingolimod (< 18 Years) | Fingolimod > 18 Years | Total |
|---|---|---|---|
| Mean | 12.8 ± 1.60 | 32.3 ± 9.11 | 30.1 ± 10.58 |
| Sex: Female, Male(Participants) | Fingolimod (< 18 Years) | Fingolimod > 18 Years | Total |
|---|---|---|---|
| Female | 3 | 51 | 54 |
| Male | 8 | 36 | 44 |
| Race (NIH/OMB)(Participants) | Fingolimod (< 18 Years) | Fingolimod > 18 Years | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 11 | 87 | 98 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Age categorical(Participants) | Fingolimod (< 18 Years) | Fingolimod > 18 Years | Total |
|---|---|---|---|
| Children 2-11 years | 2 | 0 | 2 |
| Adolescents 12-17 years | 9 | 0 | 9 |
| Adults 18-64 years | 0 | 87 | 87 |
| Number of relapses in the last 12 months prior to screening(relapses/year) | Fingolimod (< 18 Years) | Fingolimod > 18 Years | Total |
|---|---|---|---|
| Mean | 1.7 ± 1.27 | 1.2 ± 0.47 | 1.3 ± 0.62 |
| Number of relapses in 12 to 24 months prior to screening(relapses/year) | Fingolimod (< 18 Years) | Fingolimod > 18 Years | Total |
|---|---|---|---|
| Mean | 0.8 ± 1.25 | 0.7 ± 0.84 | 0.7 ± 0.89 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Feb 2021 to primary completion in Mar 2025, 49 months.
Results were first posted in Aug 2025, 5 months after primary completion.
Of 36 industry-sponsored phase 4 interventional studies under Multiple Sclerosis, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 37. This study's 49 months is above that.
Counting every sponsor, half of 69 studies reached it within 34 months; a quarter within 23 and three quarters within 59.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fingolimod